



Programme scientifique de la CCRC virtuelle de 2021

Toutes les heures sont indiquées en heure de l'Est.


Lundi 8 novembre 2021							
12 h à 12 h 15	Mots de bienvenue et d'ouverture						
12 h 15 à 13 h 45	Séance principale et table ronde – Personnalisation des mégadonnées						
13 h 45 à 14 h	Pause						
14 h à 14 h 15	LS -1A - Séance et discussion éclair – Soins palliatifs	ORAL 1A - Séance parallèle avec questions et réponses – Microenvironnement tumoral et immunologie	ORAL 1B - Séance parallèle avec questions et réponses – Approches des essais cliniques sur le cancer	Séminaire - Recherche menée par les Autochtones et gouvernance des données dans la lutte contre le cancer			
14 h 15 à 14 h 30	LS 1B - Séance et discussion éclair – Services et politiques de santé						
14 h 30 à 14 h 45							
14 h 45 à 15 h							
15 h à 15 h 15	Pause						
15 h 15 à 15 h 30	LS 1C - Séance et discussion éclair – Cancer du sang	ORAL 1C - Séance parallèle avec questions et réponses – Immunothérapie	ORAL 1D - Séance parallèle avec questions et réponses – Recherche sur le cancer chez les Autochtones				
15 h 30 à 15 h 45							
15 h 45 à 16 h	LS 1D - Séance et discussion éclair – Cancer du pancréas						
16 h à 16 h 15							
16 h 15 à 16 h 30	Synthèse de fin de journée						




Mardi 9 novembre					
12 h à 12 h 15	Mots de bienvenue et d'ouverture				
12 h 15 à 13 h 45	Séance principale et table ronde – Bien vieillir avec le cancer				
13 h 45 à 14 h	Pause				
14 h à 14 h 15	LS 2A - Séance et discussion éclair – Cancer du sein	LS 2B - Séance et discussion éclair – Cancer du cerveau	ORAL 2A - Séance parallèle avec questions et réponses – Médecine de précision et biomarqueurs	ORAL 2B - Séance parallèle avec questions et réponses – Résultats rapportés par les patients et expérience des patients	Séminaire - Recherche éthique auprès des Premières Nations, des Inuits et des Métis
14 h 15 à 14 h 30	LS 2C - Séance et discussion éclair – Cancer colorectal	LS 2D - Séance et discussion éclair – Cancer du poumon			
14 h 30 à 14 h 45					
14 h 45 à 15 h					
15 h à 15 h 15	Pause				
15 h 15 à 15 h 30	LS 2E - Séance et discussion éclair – Cancer pédiatrique	LS 2F - Séance et discussion éclair – Cancers rares	ORAL 2C - Séance parallèle avec questions et réponses – Métastases	Séance parallèle – Plateformes de recherche sur le cancer	
15 h 30 à 15 h 45					
15 h 45 à 16 h	LS 2G - Séance et discussion éclair – Cancer de la prostate	LS 2H - Séance et discussion éclair – Cancer de l'ovaire			
16 h à 16 h 15					
16 h 15 à 16 h 30	Synthèse de fin de journée				



Mercredi 10 novembre				
12 h à 12 h 15	Mots de bienvenue et d'ouverture			
12 h 15 à 12 h 30	LS 3A - Séance et discussion éclair – Létalité synthétique	ORAL 3A - Séance parallèle avec questions et réponses – COVID-19 et le dépistage et le traitement du cancer	ORAL 3B - Séance parallèle avec questions et réponses – Mode de vie et régime alimentaire	
12 h 30 à 12 h 45				
12 h 45 à 13 h	LS 3B - Séance et discussion éclair – Métastases hépatiques			
13 h à 13 h 15				
13 h 15 à 13 h 30	Pause			
13 h 30 à 15 h	Séance principale et table ronde – Les traitements anticancéreux de demain aujourd'hui			
15 h à 15 h 15	Pause			
15 h 15 à 15 h 30	LS 3C - Séance et discussion éclair – Bio-informatique et génomique	ORAL 3C - Séance parallèle avec questions et réponses – Métabolisme	ORAL 3D - Séance parallèle avec questions et réponses – L'équité dans les soins en cancérologie	
15 h 30 à 15 h 45				
15 h 45 à 16 h	LS 3D - Séance et discussion éclair – Dommages et réparation de l'ADN			
16 h à 16 h 15				
16 h 15 à 16 h 30	Synthèse de fin de journée			



Jeudi 11 novembre				
12 h à 12 h 15	Mots de bienvenue et d'ouverture			
12 h 15 à 12 h 30	LS 4A - Séance et discussion éclair – Chimiorésistance	ORAL 4A - Séance parallèle avec questions et réponses – Épigénétique	ORAL 4B - Séance parallèle avec questions et réponses – Imagerie et radio- oncologie	
12 h 30 à 12 h 45				
12 h 45 à 13 h	LS 4B - Séance et discussion éclair – Oncologie gériatrique			
13 h à 13 h 15				
13 h 15 à 13 h 30	Pause			
13 h 30 à 13 h 45	LS 4C - Séance et discussion éclair – Prévention	ORAL 4C - Séance parallèle avec questions et réponses – Mobilisation des patients	ORAL 4D - Séance parallèle avec questions et réponses – Bio- informatique et intelligence artificielle (IA)	
13 h 45 à 14 h				
14 h à 14 h 15	LS 4D - Séance et discussion éclair – Risque de cancer et prévention primaire			
14 h 15 à 14 h 30				
14 h 30 à 14 h 45	Pause			
14 h 45 à 16 h 15	Séance principale et table ronde – Comprendre et gérer les risques – La saga du cancer héréditaire			
16 h 15 à 16 h 30	Synthèse de la CCRC de 2021			



Lundi 8 novembre 2021

12 h à 12 h 15**Mots de bienvenue et d'ouverture****12 h 15 à 13 h 45****Séance principale et table ronde – Personnalisation des mégadonnées****Moderators:**

Dr. Claudia Kleinman
McGill University, Lady Davis Institute

Dr. Don Desserud
Patient Partner

Dawn of Digital Pathology: Leveraging AI for Cancer Biomarker Discovery

Dr. Ali Bashashati
University of British Columbia, Vancouver Coastal Health Research Institute

**Using Big Data to advance Precision Medicine in Oncology:
Opportunities and Challenges**

Dr. Hermann Nabi
Social and Preventive Medicine, Université Laval

PROFYLE: The Canadian Pediatric Precision Oncology Initiative

Dr. Rebecca Deyell
Pediatrics, University of British Columbia

13 h 45 à 14 h**Pause****14 h à 15 h****ORAL 1A - Séance parallèle avec questions et réponses – Microenvironnement tumoral et immunologie****Chairs:**

Dr. Paola Marcato
*Dalhousie University, Beatrice Hunter
Cancer Research Institute*

Mrs. Heather Hogan
Patient Partner

Investigating Intra-Tumour Metabolic Heterogeneity in Triple-Negative Breast Cancer


Marina Fukano
McGill University

Harnessing synthetic lethality to drive ferroptosis in hypoxic solid tumours

Dr. Shawn Chafe
BC Cancer Research Institute

Cancer cell plasticity leads to the activation of progenitor-like signaling pathways and immune checkpoint genes

Dr. Iacovos Michael
Sunnybrook Research Institute



ORAL 1B - Séance parallèle avec questions et réponses – Approches des essais cliniques sur le cancer**Chairs:**

Dr. Madeline Li
University Health Network, Princess Margaret Cancer Centre

Ms. Nathalie Baudais
Patient Partner

The Rethinking Clinical Trials (REaCT) program: leading pragmatic, practice-changing, patient-centred research across Canada

Dr. Mark Clemons
Ottawa Hospital

PAROLE-Onco, accompanying patients as members of the care team: mirage or reality?

Dr. Marie-Pascale Pomey
Centre de recherche du CHUM

Protocol for implementing a national exercise oncology program: Project EXCEL

Dr. S. Nicole Culos-Reed
University of Calgary

Séminaire - Recherche menée par les Autochtones et gouvernance des données dans la lutte contre le cancer**Facilitator:**

Melissa Cernigoy
Canadian Partnership Against Cancer

Indigenous-led research and data governance in cancer control is an emerging area of science that requires specialized knowledge and expertise. For example, current gaps in Indigenous cancer research and data systems exist within Canada while little exploration has been done to summarize existing promising practices in Indigenous cancer control data and research. In response, the Canadian Partnership Against Cancer is working with the an Indigenous Team, including the Alberta First Nations Information Governance Centre to undertake an environmental scan and engage relevant stakeholders on a regional, national and international scale. The project is designed to address the following aims:

1. To inform the implementation of the CPAC 2022-2027 Business Plan to be responsive to new and existing partner needs and aligning actions with the health system for FNIM governed research and data systems

2. To synthesize and integrate the key findings of the environmental scan engagement components for people-specific Indigenous governed research data systems and promising practices in cancer control data and research

This presentation will meet the following 3 objectives:


1. Provide an overview of the project, including guiding questions and primary activities

2. Present key findings from the environmental scan of published literature, Indigenous-led research, and relevant organizational reports, documents and frameworks

3. Discuss a holistic Indigenous model developed for data and information synthesis and interpretation grounded in Indigenous knowledge and conceptualizations of heart, spirit and mind

Dr. Angeline Letendre
Canadian Indigenous Nurses Association, Alberta Health Services

Ms. Lea Bill
Canadian Indigenous Nurses Association



14 h à 14 h 30**LS -1A - Séance et discussion éclair – Soins palliatifs**

The PROVIEW+ tool: Validating a cancer model to predict risk of death, poor performance status and severe symptoms over time

Dr. Hsien Seow
McMaster University

Using stakeholder engagement to inform Canadian Cancer Society's position statement on medical assistance in dying (MAiD)

Ms. Ruhi Kiflen
Canadian Cancer Society

Acceptability of Automatic Referrals to Supportive and Palliative Care by Patients Living with Advanced Lung Cancer: A Co-Design Process

Dr. Aliyah Pabani
University of Calgary

Does early palliative care reduce end-of-life healthcare costs: A population-based, propensity-score matched cohort study

Dr. Hsien Seow
McMaster University

Palliative home care and emergency department visits in the last 30 and 90 days of life: a retrospective cohort study of cancer patients

Ms. Jennifer Mracek
University of Calgary

14 h 30 à 15 h**LS 1B - Séance et discussion éclair – Services et politiques de santé**

The Use of Risk-Sharing Agreements to Reimburse High-Cost Oncology Drugs: Legal, Regulatory and Policy Considerations

Melanie McPhail
Simon Fraser University

Lung cancer care in Saskatchewan and Ontario: An interprovincial analysis of patient characteristics and survival outcomes

Mr. Dmitry Neymark
University of Saskatchewan

Preliminary evaluation results of the integrated knowledge translation approach utilized in the Canadian Population Attributable Risk of Cancer (ComPARe) study

Apiramy Jeyapalan
Canadian Cancer Society


The use of complementary medicine among individuals with cancer: Standardizing assessment and documentation and evaluating prevalence and associations of use


Dr. Lynda Balneaves
University of Manitoba

Characterizing the financial burden of advanced cancer: interim analysis of financial effects data from people living with advanced colorectal cancer

Dr. Marc Kerba
University of Calgary

15 h à 15 h 15**Pause**

15 h 15 à 16 h 15**ORAL 1C - Séance parallèle avec questions et réponses – Immunothérapie****Chairs:**Dr. Shashi Gujar
*Dalhousie University*Ms. Chantale Thurston
*Patient Partner***The spatial immune landscape of cutaneous melanoma**Dr. Ian Watson
*Goodman Cancer Research Centre, McGill University***Targeting CXCR2-mediated neutrophil recruitment to non-small cell lung cancer**Mr. Simon Milette
*McGill University***Elucidating the Role of the non-Receptor Tyrosine Kinase Fes in Tumour Immune Evasion**Mr. Brian Laight
*Queen's University***ORAL 1D - Séance parallèle avec questions et réponses – Recherche sur le cancer chez les Autochtones**Dr. Brenda Elias
*University of Manitoba*Ms. Louise Bird
*Patient Partner***Re-conceptualizing Metrics for an Indigenous Cancer Indicator Framework on Cancer Screening to Early Diagnosis and through the Cancer Journey**Dr. Angeline Letendre
*Canadian Indigenous Nurses Association***Exploring the cancer experiences and outcomes for Metis patients and families in Saskatchewan**Mr. Adel Panahi and Miss Tegan Brock
*Metis Nation - Saskatchewan***The Manitoba Metis Cancer Journey**Ms. Julianne Sanguins
*Manitoba Metis Federation***15 h 15 à 15 h 45****LS 1C - Séance et discussion éclair – Cancer du sang****Transient receptor potential vanilloid type calcium channel (TRPV6) as a novel therapeutic target in lymphoid tumours**Dr. Alli Murugesan
*University of New Brunswick***Molecular Subtyping of NPM1 mutated AML**Dr. Arvind Mer
*Princess Margaret Cancer Centre***Defining the biological significance and role of somatic TMEM30A mutations in diffuse large B cell lymphoma.**Shannon Healy
*BC Cancer Agency***A modular activatable synthetic biology system to visualize in vivo cell-cell communication**Mr. TianDuo Wang
*Robarts Research Institute***Mathematical modelling of perturbed hematopoiesis during the pre-leukemic phase of AML to evaluate therapeutic strategies for clonal reduction**Mia Brunetti
Université de Montréal

15 h 45 à 16 h 15**LS 1D - Séance et discussion éclair – Cancer du pancréas****Exploring the effects of SBRT on the pancreatic tumor microenvironment using intravital fluorescence microscopy**Mr. Timothy Samuel
*University Health Network***TANDEM: Biomicrofluidic Systems with Transverse And Normal Diffusional Environments for Multidirectional Signalling**Mr. Michael Mohan
*University of Toronto***The Role of Neutrophil Extracellular Trap/CCDC25/Integrin Linked Kinase in Pancreatic Ductal Adenocarcinoma (PDAC) Progression and Metastasis**Dr. Paul McDonald
*BC Cancer Research Institute***16 h 15 à 16 h 30****Synthèse de fin de journée****Mardi 9 novembre****12 h à 12 h 15****Mots de bienvenue et d'ouverture****12 h 15 à 13 h 45****Séance principale et table ronde – Bien vieillir avec le cancer****Moderators:**Dr. Martine Puts
*University of Toronto*Ms. Debi Lascelle
*Patient and Family Representative*Dr. Ronald DePinho
*MD Anderson Cancer Center***Telomeres in Cancer and Aging****Aging well during and after cancer therapies**Dr. Shabbir Alibhai
*Medicine, University Health Network***Working with older adults as they manage cancer: Evidence & opportunities**Dr. Kristen Haase
*School of Nursing, University of British Columbia***Dignity and Personhood in the Terminally Ill**Dr. Harvey Chochinov
*University of Manitoba***13 h 45 à 14 h****Pause**

14 h à 15 h

ORAL 2A - Séance parallèle avec questions et réponses – Médecine de précision et biomarqueurs**Chairs:**Dr. Elena Kuzmin
*Concordia University, McGill University*Dr. Christine Wu
*Patient Partner***From cell signaling to drug targeting in melanoma**Dr. Ian Watson
*Goodman Cancer Research Centre, McGill University***Deciphering intra-tumoral heterogeneity in multiple myeloma: A single cell study**Dr. Ali Mahdipour Shirayeh
*University of Toronto***The receptor for hyaluronan-mediated motility as a regulator of drug sensitivity in triple-negative breast cancer**Ms. Britney Messam
*Western University***ORAL 2B - Séance parallèle avec questions et réponses – Résultats rapportés par les patients et expérience des patients****Chairs:**Dr. Lynn Gauthier
*Research-Centre of the CHU de Québec,
Cancer Research Centre, Université Laval*Ms. Donna Pepin
*Patient Partner***Harnessing the Power of Integrated Patient Reported Outcomes (PROs): Exploring the Relationship Between Symptom Complexity and Health System Utilization**Dr. Linda Watson
*Alberta Health Services***Cancer Journey Experiences of Métis Albertans**Ms. June Kima
*The Métis Nation of Alberta***Experiences and Perceptions of Older Adults with Lower-risk Hormone Receptor-positive Breast Cancer about Adjuvant Radiotherapy and Endocrine Therapy: A Patient Survey**Dr. Marie-France Savard
*University of Ottawa***Séminaire - Recherche éthique auprès des Premières Nations, des Inuits et des Métis****Facilitator:**Dr. Sara Urowitz
Canadian Cancer Research Alliance, Canadian Partnership Against Cancer

Sponsored by:



Join this "fireside chat" to gain a better understanding about how researchers and Indigenous community leaders engage in health/cancer related research that is ethical and benefits First Nations, Inuit and Métis. Three panelists will share their thoughts, experiences and opinions on how they have built ethical research partnerships, included diverse perspectives in their research and are guided by First Nations, Inuit and Métis research principles and protocols.

Mr. Adel Panahi
*Métis Nation – Saskatchewan*Dr. Gary Groot
*University of Saskatchewan*Dr. Jennifer Shea
Memorial University

14 h à 14 h 30

LS 2A - Lightning Session and Discussion - Breast Cancer

Emergence of B1 integrin-deficient mammary tumors from dormancy involves both epithelial cell intrinsic and extrinsic mechanisms	Miss Yu Gu <i>McGill University</i>
Developing a model of HER2+/ER+ breast cancer to examine the role of the immune microenvironment on therapeutic response	Miss Hailey Dall-Proud <i>McGill University</i>
Inhibiting the adaptor protein ezrin enhances adaptive anti-tumor immune responses in a mouse model of triple-negative breast cancer	Dr. Victoria Hoskin <i>Queen's University</i>
Using Machine Learning to Identify Risk Factors for Severe Vasomotor Symptoms in Breast Cancer Patients	Dr. Katherine Cole <i>University of Ottawa</i>
Dissecting novel ShcA-regulated signalling networks that promote breast cancer progression and therapeutic resistance.	Miss Kathryn Hunt <i>McGill University</i>


LS 2B - Séance et discussion éclair – Cancer du cerveau

Regulation of mRNA translation by eIF5B in glioblastoma	Dr. Nehal Thakor <i>University of Lethbridge</i>
Invasive growth of brain metastases is driven by cancer cell-pSTAT3+ reactive astrocyte crosstalk	Ms. Sarah Maritan <i>McGill University</i>
Cell Cycle Regulation as a Permissive Early Event During Gliomagenesis	Dr. Lisa Porter <i>University of Windsor</i>
Glioblastoma Temozolomide Chemoresistance: Is Autophagy Playing a Role?	Miss Courtney Clark <i>University of Manitoba</i>
The Role of RNA Methyltransferase NSUN5 in Translational Reprogramming and Tumorigenesis in Glioblastoma	Yan Shu Kong <i>University of Alberta</i>

14 h 30 à 15 h

LS 2C - Séance et discussion éclair – Cancer colorectal

A systematic review of colorectal cancer prevention and screening interventions among Indigenous populations in Canada and abroad	Ms. Eleeyah Uri <i>Ontario Health</i>
Evaluation of algorithms using administrative health and structured electronic medical record data to determine breast and colorectal cancer recurrence in a Canadian province	Mr. Pascal Lambert <i>CancerCare Manitoba</i>
Treatment patterns and survival outcomes of early age-at-onset colorectal cancer patients in Alberta: a population-based study	Dr. Dylan O'Sullivan <i>University of Calgary</i>



Genomic instability and DNA damage regulate STING activation through characteristic cytosolic DNA structures in colorectal cancer

Shayla Mosley
University of Alberta

Analyzing tumour infiltrating lymphocyte populations in MSI vs. MSS primary colon cancer patients using digital cytometry

Ms. Sara Pietropaolo
Dalhousie University

LS 2D - Séance et discussion éclair – Cancer du poumon Cancer

Création et caractérisation d'une cohorte provinciale de patients atteints d'un cancer du poumon à l'aide de données clinico-administratives

Mr. Gino Boily
Institut d'excellence en santé et en services sociaux

Examining the Relationship Between Green Space, Air Pollution, and Lung Cancer Incidence Using Bayesian Hierarchical Modelling.

Mr. Jonathan Simkin
BC Cancer

Perspectives of family physicians towards access to lung cancer screening for individuals living with low income

Dr. Ambreen Sayani
Women's College Hospital

Infrared Spectroscopic Analysis of Exhaled Breath for Prediction of Progression-Free and Overall Survival in Lung Cancer Patients

Ms. Erin Brooks
Dalhousie University

Non-small cell lung cancer survival by immigrant status: A population-based retrospective cohort study in Ontario, Canada

Dr. Geetanjali Datta
Cedars-Sinai Medical Centre

15 h à 15 h 15

Pause

15 h 15 à 16 h 15

ORAL 2C - Séance parallèle avec questions et réponses – Métastases

Chairs:

Dr. Amina Zoubeidi
University of British Columbia

Ms. Cathie Hays
Patient Partner

3D Chromatin Remodeling Potentiates Transcriptional Programs Driving Cell Invasion


Dr. Michael Witcher
The Lady Davis Institute of McGill University

Proteomic screens for suppressors of anoikis identify IL1RAP as a promising surface target in Ewing sarcoma

Dr. Haifeng Zhang
University of British Columbia

Neutrophil oxidative stress mediates obesity-associated vascular inflammation and metastatic transmigration

Sheri McDowell
McGill University



Séance parallèle – Plateformes de recherche sur le cancer

Chairs:

Ms. Kimberly Badovinac

Canadian Cancer Research Alliance, Canadian Partnership Against Cancer

The Canadian Tissue Repository Network CTRNet; update on biospecimen and data resources and tools to help cancer researchers

Dr. Anne-Marie Mes-Masson
Centre de recherche du CHUM

CanPath: A national platform for health research

Dr. Peter Watson
BC Cancer

Networked Support for Canada's Academic Cancer Trial Environment

Dr. Trevor Dummer
University of British Columbia

Marathon of Hope Cancer Centres Network and Digital Health and Discovery Platform

Mr. Stephen Sundquist
3CTN - Canadian Cancer Clinical Trials Network

15 h 15 à 15 h 45

LS 2E - Séance et discussion éclair – Cancer pédiatrique

Hearing Loss in Cisplatin-Treated Childhood Cancer Patients is Mediated by Toll-Like Receptor 4

Ms. Asna Latif
University of Alberta

Potential pro-leukemic signaling through Toll-like receptor 3 in pediatric acute lymphoblastic leukemia

Ms. Tammaya Atre
BC Children's Hospital Research Institute

Understanding and preventing acute lymphoblastic leukemia late adverse effects using genomics and machine learning

Mr. Nicolas Raymond
Université de Sherbrooke

Genetic and Transcriptional analysis of Patient-Derived Xenografts (PDXes) for Leptomeningeal Disease

Miss Ana Isabel Castillo Orozco
McGill University, RI-MUHC

LS 2F - Séance et discussion éclair – Cancers rares

STING Activation in Sarcoma: Assessing Clinically Relevant Therapeutic Strategies

Ms. Karys Hildebrand
University of Calgary

Development of targeted radioimmunotherapy for osteosarcoma using comparative oncology approach


Mr. Chandra Bose Prabaharan
University of Saskatchewan

Characterization of metabolic rewiring and identification of potential therapeutic targets in CBFA2T3-GLIS2-dependent AMKL

Dr. Caroline Capdevielle
Centre de recherche HMR

Tumorigenic properties of uveal melanoma cancer cells grown in 3D or on a reconstructed extracellular matrix

Oliver Chancy
Université Laval



Alterations on intracellular localization and trafficking of the RET receptor induced by Multiple Endocrine Neoplasia type 2 mutations

Mr. Eduardo Reyes-Alvarez
Queen's University

15 h 45 à 16 h 15

LS 2G - Séance et discussion éclair – Cancer de la prostate

Clinical and genomic indolence in lung recurrent metastatic hormone-sensitive prostate cancer

Dr. Nicolette Fonseca
University of British Columbia

Identifying Circulating Genes to Stratify Patients with Advanced Prostate Cancer and Predict Therapeutic Response

Miss Seta Derderian
RI-MUHC

Identification of Cellular Signatures Predictive of Human Prostate Cancer Progression

Ms. Chloe Liu
McGill University, Goodman Cancer Research Centre

The role of receptor tyrosine kinase ROR2 in stemness and immune evasion

Ms. Nakisa Tabrizian
University of British Columbia / Vancouver Prostate Centre

The gut microbiome-prostate tumour crosstalk is modulated by dietary polyunsaturated fatty acids

Mr. Jalal Laaraj
Centre de recherche du CHU de Québec-Université Laval

LS 2H - Séance et discussion éclair – Cancer de l'ovaire

Targeting NAD metabolism counters PARP inhibitor resistance in ovarian cancer

Mr. Alex Sauriol
Institut du cancer de Montréal

Cystathione gamma lyase: A promising therapeutic target in clear cell carcinoma of the ovary

Dr. Amal EL-Naggar
University of British Columbia

Development of theranostic probes against MUC16 to enable PET/CT imaging for early detection and targeted radioimmunotherapy of MUC16 expressing ovarian cancers.

Miss Hanan Babeker
University of Saskatchewan

Oviduct epithelial cells constitute two developmentally distinct lineages that are spatially separated along the distal-proximal axis


Dr. Matthew Ford
McGill University, Goodman Cancer Research Centre

Developing an ovarian cancer tissue cell fate (TCFate) manipulation and detection tool

Miss Marie Orléan ADA NDONG
Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM)

16 h 15 à 16 h 30

Synthèse de fin de journée



Mercredi 10 novembre

12 h à 12 h 15**Mots de bienvenue et d'ouverture****12 h 15 à 13 h 15****ORAL 3A - Séance parallèle avec questions et réponses – COVID-19 et le dépistage et le traitement du cancer****Chairs:**Dr. Timothy Hanna
*Queen's University*Ms. Melissa Coombs
*Patient Partner***Predicted impact of the COVID-19 pandemic on cancer incidence and mortality in Canada**Dr. Talía Malagón
*McGill University***Utilization of COVID-19 related funding modifications for systemic cancer therapies in Ontario, Canada**Ms. Jaclyn Beca
*Ontario Health***Evaluating the impact of the COVID-19 pandemic on new cancer diagnoses and oncology care in Manitoba**Dr. Kathleen Decker
*CancerCare Manitoba, University of Manitoba***ORAL 3B - Séance parallèle avec questions et réponses – Mode de vie et régime alimentaire****Chairs:**Dr. P. Peter Wang
*University of Toronto*Mr. Archie Stewart
*Patient Partner***Psychiatric Disorder Incidence Among Adolescents and Young Adults Aged 15-39 with Cancer: A Population-Based Cohort Study**Dr. Miranda Fidler-Benaoudia
*University of Calgary***The Association of Estimated Cardiorespiratory Fitness and Overweight and Obesity with Invasive Breast Cancer: A prospective cohort study**Miss Rebecca Christensen
*University of Toronto***Investigating the relationship between heavy metal exposure and cancer risk in Canada**Miss Katherine Pullella
*University of Toronto***12 h 15 à 12 h 45****LS 3A - Séance et discussion éclair – Létalité synthétique****Preclinical Studies on Novel Treatment Plans for Metastatic Triple Negative Breast Cancers**Dr. Armin Gamper
*University of Alberta, Cross Cancer Institute***Genome-Wide CRISPR Cas9 Screen Reveals a Synthetic Lethal Interaction Between PARG and PTEN in Melanoma**Mr. Emmanuel Asante
*McGill University***Genome-wide CRISPR Screens Identify Ferroptosis as a Novel Therapeutic Vulnerability in Acute Lymphoblastic Leukemia**Dr. Marie-Eve Lalonde
National Research Council

The roles of 4E-BP1 in breast cancer metastasisMr. Predrag Jovanovic
*Lady Davis Institute***Characterizing the role of ETFDH on cancer biology**Dr. David Papadopoli
*Lady Davis Institute***12 h 45 à 13 h 15****LS 3B - Séance et discussion éclair – Métastases hépatiques****The role of Estrogen in the Immune Microenvironment of Liver Metastases**Miss Yasmine Benslimane
*McGill University***Immunoprofiling the Impact of Treatments on Co-opting Histological Growth Patterns of Colorectal Cancer Liver Metastases**Diane Kim
*McGill University Health Centre***EV derived Proteomics profile to stratify Angiogenic and Non-Angiogenic HGP in Colorectal Cancer Liver metastasis**Mrs. Migmar Tsamchoe
*Research Institute of McGill University Health Centre***A comprehensive analysis of SNPs and CNVs in relation to survival outcomes in colorectal cancer**Mr. Yajun Yu
*Memorial University of Newfoundland***1 h 15 à 1 h 30****Pause****13 h 30 à 15 h****Séance principale et table ronde – Les traitements anticancéreux de demain aujourd’hui****Moderators:**Dr. Madhuri Koti
*Queen's University*Ms. Ruth Ackerman
*Patient and Family Representative***Single-cell sequencing for identifying lung cancer biomarkers**Dr. Paola Marignani
*Biochemistry and Molecular Biology, Dalhousie University***Clinical Applications of Liquid Biopsy in Oncology**Dr. Lilian Siu
*University Health Network***From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy**Dr. Padmanee Sharma
MD Anderson Cancer Centre

13 h 15 à 13 h 30


Pause

15 h 15 à 16 h 15**ORAL 3C - Séance parallèle avec questions et réponses – Métabolisme**

Chairs:

Dr. Rachel Murphy
*University of British Columbia*Mr. Angus Pratt
*Patient Partner***Mevalonate metabolism as an actionable vulnerability of t(4;14)-positive multiple myeloma**Dr. Joseph Longo
*Van Andel Institute***Metabolic adaptations supporting the evolution of resistance to chemotherapeutics in breast cancer**Mr. Yannick Audet-Delage
*University of Ottawa***Targeting metabolism as a novel therapeutic strategy to suppress oncogenic MYC in group 3 medulloblastoma tumors**Emma Martell
*University of Manitoba***ORAL 3D - Séance parallèle avec questions et réponses – L'équité dans les soins en cancérologie**

Chairs:

Dr. Erin Strumpf
*McGill University*Ms. Mei-Lin Yee
*Patient Partner***Building on Existing Tools to Improve Chronic Disease Prevention and Screening in Public Health: A Cluster Randomized Trial**Dr. Aisha Lofters
*Women's College Hospital***Exploring Health Equity in a Context of Cancer Prevention from Alberta Métis Perspectives**Dr. Angeline Letendre
*Canadian Indigenous Nurses Association***High prevalence of triple negative and quadruple negative breast cancer among women of African ancestry compared to Caucasian women**Shawn Hercules
*McMaster University***15 h 15 à 15 h 45****LS 3C - Séance et discussion éclair – Bio-informatique et génomique****Circulating-tumour DNA Derived Nucleosome Positioning Captures Tissue Gene Expression And Transcription Factor Activity In Prostate Cancer**Ms. Xinyi Chen
*Vancouver Prostate Centre***In-silico selection of potential overexpressed cancer protein markers in blood plasma samples**Dr. Huiyan Li
University of Guelph

Application of Generalized Multifactor Dimensionality Reduction (GMDR) methods to identify potential multi-SNP interactions associated with survival times in colorectal cancer patients

Mr. Aaron Curtis
Memorial University of Newfoundland

Orchestrating and sharing large multimodal biomedical data for more transparent and reproducible biomarker discovery

Dr. Benjamin Haibe-Kains
University Health Network

LDCT Lung Sub-cm Nodule Malignancy Prediction with Combination Radiomics and Machine Learning Models

Mr. Ian Janzen
BC Cancer

15 h 45 à 16 h 15

LS 3D - Séance et discussion éclair – Dommages et réparation de l'ADN

Investigation of the sexual dimorphic tumor suppressor role of DDX3X in melanoma

Mrs. Marine Lingrand
McGill University

High sensitivity of p53 mutated sonic hedgehog medulloblastoma to ATM inhibition

Mrs. Niusha Khazaei
McGill University

The role of HORMAD1 in DNA damage repair in squamous cell carcinomas

Mrs. Jennifer Gantchev
McGill University

Revival Stem Cells Mediate P53-Dependent DNA Repair to Regenerate the Intestinal Epithelium

Dr. Arshad Ayyaz
Mount Sinai Hospital

Beyond BRCA1 during DNA repair by homologous recombination (HR): characterization of the zinc finger protein POGZ as a novel pro-HR factor

Dr. Alexandre Orthwein
Lady Davis Institute


16 h 15 à 16 h 30

Synthèse de fin de journée

Jeudi 11 novembre

12 h à 12 h 15

Mots de bienvenue et d'ouverture



12 h 15 à 13 h 15

ORAL 4A - Séance parallèle avec questions et réponses – Épigénétique

Chairs:

Dr. Gareth Williams
University of Calgary

Dr. Rosilene Kraft
Patient Partner

MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets

Dr. David Labbé
McGill University

Uncovering the dosage-dependent roles of Arid1a in gastric tumorigenesis for combinatorial drug therapy

Mr. Adrian Loe
Hospital for Sick Children

Systematic characterization of the bromodomain containing subunits within the mSWI/SNF chromatin remodeling complexes

Miss Lynda AGBO
Université Laval

ORAL 4B - Séance parallèle avec questions et réponses – Imagerie et radio-oncologie

Chairs:

Dr. Nawaid Usmani
University of Alberta

Ms. Katey Thompson
Patient Partner

Predicting Prostate Cancer Response to Brachytherapy Using AI Driven Digital Pathology

Dr. Calum MacAulay
BC Cancer

Ionizing radiation upregulates TKS5 expression in Glioblastoma

Ms. Lisa Decotret
BC Cancer

Anti-hypertensive Drug Modulates Cancer-Associated Fibroblasts to Improve Radiation Response

Ms. Che-Min Lee
BC Cancer Research Centre

12 h 15 à 12 h 45

LS 4A - Séance et discussion éclair – Chimiorésistance

Overcoming cancer recurrence and metastatic progression by targeting anastasis

Dr. Wells Brown
British Columbia Cancer Research Institute

Identify Targetable Molecular Drivers of Chemotherapy Resistance in Gastro-Esophageal Adenocarcinoma

Ms. Iris Kong
McGill University

SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca²⁺ flux to mitochondria

Miss Kangning Yang
McGill University


Reciprocal metabolic and epigenetic adaptations to microenvironment stress exposes vulnerabilities in breast cancer

Ms. Geneviève Deblois
Université de Montréal

Immune checkpoint inhibitor resistance mutations in the IFN-JAK-STAT pathway increase melanoma sensitivity to oncolytic virus treatment

Dr. Ian Watson
Goodman Cancer Research Centre, McGill University



12 h 45 à 13 h 15**LS 4B - Séance et discussion éclair – Oncologie gériatrique****Identifying gaps in the care of older Albertans with cancer: Analysis of patient-reported, clinical, administrative, and survey datasets**Dr. Fay Strohschein
*University of Calgary***Prevalence of Preexisting Cognitive Impairment in Patients Treated for Cancer and Its Impact on Cognitive Outcomes**Nelly Toledoano
*University of Toronto***Care Provided by Older Adult Caregivers to a Spouse in Active Cancer Treatment: A Scoping Review**Mrs. Valentina Donison
*University of Toronto***Comprehensive geriatric assessment and management for Canadian elders with Cancer: the 5C study**Dr. Martine Puts
*University of Toronto***Self-management interventions for issues identified in a geriatric assessment: a systematic review**Mrs. Valentina Donison
*University of Toronto***13 h 15 à 13 h 30****Pause****13 h 30 à 14 h 30****ORAL 4C - Séance parallèle avec questions et réponses – Mobilisation des patients****Chairs:**Dr. David Dawe
*CancerCare Manitoba, University of Manitoba*Ms. Michelle Stratton
*Patient Partner***The top ten research priorities for early stage colorectal cancer: A Canadian patient oriented priority setting partnership**Dr. Colleen Cuthbert
*University of Calgary***Real-world implementation of an electronic patient-reported outcomes program in cancer centres in Quebec (e-IMPAQc): successes, challenges, and lessons learned**Dr. Sylvie Lambert
*McGill University***Operationalizing Patient Identified Priorities in the Breast Cancer Community**Ms. Diana Ermel and Ms. Jenn Gordon
*Canadian Breast Cancer Network***ORAL 4D - Séance parallèle avec questions et réponses – Bio-informatique et intelligence artificielle (IA)****Chairs:**Dr. Franco Vizeacoumar
*Saskatchewan Cancer Agency,
University of Saskatchewan*Ms. Kirsten Efremov
*Patient Partner***Meta-analysis of preclinical pharmacogenomics studies for biomarker discovery**Dr. Benjamin Haibe-Kains
University Health Network

Evolution of large copy number variants in breast cancer through genetic network rewiring

Dr. Elena Kuzmin
McGill University

Multi-omic classification and characterization of pancreatic neuroendocrine neoplasms

Dr. Sharon Gorski
BC Cancer

13 h 30 à 14 h

LS 4C - Séance et discussion éclair – Prévention

Mental Health Disorders, Cancer Risk, and the Mediating Role of Health Behaviours in the CARTaGENE Cohort Study

Miss Kaitlyn Gilham
The University of British Columbia

A population-based study of salpingectomy and risk of epithelial ovarian cancer in Ontario

Mr. Vasily Giannakeas
Women's College Hospital

Long working hours and prostate cancer risk: results from a population-based case-control study

Miss Charlotte Salmon
Institut national de la recherche scientifique - Centre Armand-Frappier Santé Biotechnologie

Synergistic effects of combined inflammatory cytokines IFNy, IL1 β , TNFa, and TGF β , on the proliferation and gene expression of breast cancer cells

Mr. Jorge Alfonso Leon Machado
Université de Sherbrooke

Dietary antioxidant formulation reduces carcinogen-induced DNA damage in bronchial epithelial cells in vitro

Dr. Jose Merlin Jayaraj
Dalhousie University

14 h à 14 h 30

LS 4D - Séance et discussion éclair – Risque de cancer et prévention primaire

Effets de pesticides agricoles sur le transcriptome de cellules cancéreuses

Miss Nadia Côté
Université de Sherbrooke

Sleep duration and ovarian cancer risk

Mrs. Flavie Marquis
Université de Montréal

Omega-3 fatty acids and inflammatory markers expression in normal breast tissue


Dr. Kaoutar Ennour-Idrissi
Laval University

Quality of life for men at risk of prostate cancer: a descriptive analysis from a large Canadian cohort

Ms. Roxane Tourigny
CHU de Québec, Université Laval

UVR on skin tissues induce the retrotransposon LINE-1 expression reactivation

Miss Marine Lambert
Research Institute of MUHC



14 h 30 à 14 h 45

Pause

14 h 45 à 16 h 15**Séance principale et table ronde – Comprendre et gérer les risques – La saga du cancer héréditaire****Moderators:**

Dr. Jacque Simard Ms. Nathalie Baudais
Centre de recherche du CHU de Québec, Patient and Family Representative
Université Laval

The cellular specificity of hereditary cancers syndromes: two short stories

Dr. David Huntsman
BC Cancer, University of British Columbia

The Saga of Hereditary Cancer 1987 to 2021

Dr. Steven Narod
Women's College Research Institute

Family Histories and Hereditary Cancer Services: minimizing the bottleneck and opening the bottle

Dr. Nadine Caron
University of Northern British Columbia

16 h 15 à 16 h 30**Synthèse de la CCRC de 2021**